CHI-MED

HUTCHISON CHINA MEDITECH LTD
INVESTOR RELATIONS

Announcements

19 September 2014 TR-1: Notification of major interest in shares  
21 August 2014 Patient enrolment completed ahead of schedule for fruquintinib's Phase II study in colorectal cancer  
13 August 2014 HMPL-004 NATRUL-3 interim analysis result  
29 July 2014 Interim Results for the Six Months Ended 30 June 2014  
30 June 2014 Total Voting Rights  
30 June 2014 Blocklisting Six Monthly Return  
26 June 2014 Notice of Announcement of 2014 Interim Results  
25 June 2014 Chi-Med Refinancing of Existing Loan Facility  
18 June 2014 Initiation of Phase I clinical trial of novel Syk Inhibitor HMPL - 523 for autoimmune diseases  
05 June 2014 Initiation of fruquintinib Phase II study in non-small cell lung cancer  
04 June 2014 Director's Shareholding  
03 June 2014 Exercise of Options  
30 May 2014 Chi-Med and Shanghai Traditional Chinese Medicine expand commercial cooperation  
23 May 2014 Initiation of AZD6094 (HMPL-504/volitinib) Global Phase II Study in Papillary Renal Cell Carcinoma  
22 May 2014 Phase I clinical data for selective VEGFR, c-Met and VEGFR/FGFR inhibitors to be presented at the 2014 ASCO Annual Meeting  
08 May 2014 Results of Annual General Meeting  
17 April 2014 Chi-Med and Sinopharm complete regulatory approval for the establishment of new China drug distribution and marketing Joint Venture  
04 April 2014 Presentations of volitinib and epitinib data at the 2014 AACR Annual Meeting  
04 April 2014 Initiation of fruquintinib Phase II study in colorectal cancer  
28 March 2014 2013 Annual Report and Notice of Annual General Meeting  
18 February 2014 Final Results for the year ended 31 December 2013  
13 February 2014 TR-1: Notification of major interest in shares  
16 January 2014 Notice of Announcement of 2013 Final Results  
30 December 2013 Blocklisting Six Monthly Return  
18 December 2013 Chi-Med and Sinopharm form China drug distribution and marketing joint venture  
16 October 2013 Director's Shareholding  
09 October 2013 Chi-Med's Pharmaceutical R&D Business - Analyst & Investor Briefing  
09 October 2013 Candidate Nomination of Novel Small-Molecule Therapy in Inflammation Triggers Milestone Payment From Janssen Pharmaceuticals, Inc.  
09 October 2013 Cancer Therapy Collaboration with Lilly  
03 October 2013 Analyst briefing on Chi-Med's pharmaceutical R&D business on 9 October 2013  
13 September 2013 TR-1: Notification of major interest in shares  
08 August 2013 Director's Shareholding  
30 July 2013 Interim Results for the Six Months Ended 30 June 2013  
17 July 2013 Nutrition Science Partners announces initiation of NATRUL-4, the maintenance study of the global Phase III trial for HMPL-004  
01 July 2013 Blocklisting Six Monthly Return  
25 June 2013 Initiation of Volitinib China Phase I study triggers US$5 million milestone payment  
24 June 2013 Notice of Announcement of 2013 Interim Results  
10 May 2013 Results of Annual General Meeting  
24 April 2013 Nutrition Science Partners announces initiation and treatment of the first Ulcerative Colitis patient in the global NATRUL Phase III trial for the novel botanical oral drug HMPL-004  
12 April 2013 Nestle Health Science and Chi-Med complete regulatory approvals for the establishment of Nutrition Science Partners Joint Venture  
09 April 2013 2012 Annual Report and Notice of Annual General Meeting  
08 April 2013 Presentations of Fruquintinib Phase I Clinical Data and Volitinib Preclinical Data at the 2013 AACR Annual Meeting  
26 March 2013 Final Results for the year ended 31 December 2012  
28 February 2013 Total Voting Rights  
18 February 2013 Notice of Announcement of 2012 Final Results  
28 January 2013 TR-1: Notification of major interest in shares  
31 December 2012 Blocklisting Six Monthly Return  
28 November 2012 Chi-Med and Nestlé Health Science establish Joint Venture  
01 November 2012 Hutchison MediPharma Limited initiates Phase I clinical study with its novel EGFR inhibitor Theliatinib  
08 October 2012 TR-1: Notification of major interest in shares  
28 September 2012 Total Voting Rights  
13 September 2012 Director's Shareholding  
28 August 2012 Change of Nominated Adviser  
31 July 2012 Interim Results for the Six Months Ended 30 June 2012  
05 July 2012 Total Voting Rights  
29 June 2012 Announcement on Blocklisting Six Monthly Return  
28 June 2012 Notice of Announcement of 2012 Interim Results  
14 June 2012 Exercise of Options  
06 June 2012 Hutchison MediPharma Limited Announces Presentations of Sulfatinib and Fruquintinib Clinical Data at the 2012 ASCO Annual Meeting  
30 May 2012 Director's Shareholding  
11 May 2012 Results of Annual General Meeting  
10 April 2012 2011 Annual Report and Notice of Annual General Meeting  
20 March 2012 Final Results for the year ended 31 December 2011. Strong growth. Positive outlook  
22 February 2012 Hutchison MediPharma Limited initiates Phase I clinical study of its novel c-Met inhibitor Volitinib  
20 February 2012 Notice of Announcement of 2011 Final Results  
14 February 2012 TR-1: Notification of major interests in shares  
02 February 2012 Total Voting Rights  
05 January 2012 TR-1: Notification of major interest in shares  
29 December 2011 Blocklisting Six Monthly Return  
21 December 2011 AstraZeneca and Chi-Med enter into global collaboration to co-develop and commercialise novel cancer therapy  
12 December 2011 Chi-Med Loan Facility  
04 November 2011 Hutchison MediPharma Limited initiates Phase I clinical study for its novel EGFR inhibitor Epitinib  
05 September 2011 TR-1: Notification of major interests in shares  
01 August 2011 Interim Results for the Six Months Ended 30 June 2011  
22 July 2011 China Healthcare Division expands OTC drug distribution and marketing operations  
05 July 2011 Notice of Announcement of 2011 Interim Results  
29 June 2011 Blocklisting Six Monthly Return  
13 May 2011 TR-1: Notification of major interests in shares  
09 May 2011 Results of Annual General Meeting  
09 May 2011 TR-1: Notification of major interests in shares  
04 April 2011 2010 Annual Report and Notice of Annual General Meeting  
28 March 2011 Director's Shareholding  
09 March 2011 Final Results for the year ended 31 December 2010 Strong performance across all divisions.  
21 February 2011 Board Change  
15 February 2011 Appointment of UBS Limited as Joint Broker  
01 February 2011 Fruquintinib receives SFDA IND approval Starts Phase I Clinical Trial for the treatment of cancer  
31 January 2011 Notice of Announcement of 2010 Final Results  
05 January 2011 Total Voting Rights  
29 December 2010 Blocklisting Six Monthly Return  
21 December 2010 Hutchison MediPharma Receives Further Strategic Investment to Advance Its Pipeline  
10 December 2010 China Healthcare Division Chi-Med increases indirect ownership of its Hutchison Baiyunshan joint venture  
08 November 2010 Hutchison MediPharma Receives Strategic Investment to Advance Its Pipeline  
20 September 2010 Hutchison Hain Organic launch EARTH'S BEST® and ZHI LING TONG Co-branded Infant formula in China  
15 September 2010 Appointment of Joint Broker  
29 July 2010 Interim Results for the Six Months Ended 30 June 2010 Strong results. Continued momentum. Positive outlook.  
14 July 2010 TR-1: Notification of major interests in shares  
07 July 2010 TR-1: Notification of major interests in shares  
07 July 2010 Notice of Announcement of 2010 Interim Results  
05 July 2010 Total Voting Rights  
29 June 2010 Blocklisting Six Monthly Return  
25 June 2010 Director's Shareholding  
17 June 2010 TR-1: Notification of major interests in shares  
30 April 2010 Results of Annual General Meeting  
30 April 2010 Hutchison MediPharma Limited Receives SFDA IND Approval and Begins Phase I Clinical Trial of Sulfatinib for the Treatment of Cancer  
19 April 2010 Seven-year extension of IP protection for Chi-Med's main prescription drug  
29 March 2010 2009 Annual Report and Notice of Annual General Meeting  
15 March 2010 TR-1: Notification of major interests in shares  
12 March 2010 TR-1: Notification of major interests in shares  
10 March 2010 TR-1: Notification of major interests in shares  
08 March 2010 TR-1: Notification of Major Interests in Shares  
04 March 2010 Final Results for the year ended 31 December 2009
Strong results. Momentum continues. Positive outlook.
 
08 February 2010 Notice of Announcement of 2009 Final Results  
02 February 2010 Total Voting Rights  
19 January 2010 Three more of Chi-Med's China Healthcare Division drugs added to latest China's National Medicines Catalogue  
04 January 2010 Total Voting Rights  
29 December 2009 Blocklisting Six Monthly Return  
26 November 2009 TR-1 : Notification of Major Interests in Shares  
05 November 2009 Successful Global Phase IIb Ulcerative Colitis Trial for HMPL-004: All Primary and Secondary Endpoints Achieved Hutchison MediPharma Proceeding with Development and Partnership Plans  
30 October 2009 Hutchison MediPharma Limited Initiates Phase I Clinical Trial of HMPL-011, Its Novel Single Chemical Drug Candidate for the Treatment of Auto-immune Diseases  
26 October 2009 Chi-Med increases ownership of its Hutchison Healthcare joint venture to 100%  
16 October 2009 Newly Published China National Essential Medicines List Reference Prices No Overall Negative Impact on Chi-Med Prices  
08 October 2009 Chi-Med announces joint venture with The Hain Celestial Group to develop natural and organic consumer products in Asia  
27 August 2009 Chi-Med's Main Drugs Included in the New National Essential Medicines List  
30 July 2009 Interim Results for the Six Months Ended 30 June 2009  
29 July 2009 Patient Enrolment Completed Ahead of Schedule for the Global Phase IIb Ulcerative Colitis Trial of HMPL-004  
13 July 2009 Phase II Crohn's Disease Trial for HMPL-004 Delivers Encouraging Results  
08 July 2009 Notice of Announcement of 2009 Interim Results  
30 June 2009 Blocklisting Six Monthly Return  
08 May 2009 Results of Annual General Meeting  
09 April 2009 Director's Shareholding  
06 April 2009 2008 Annual Report and Notice of Annual General Meeting  
20 March 2009 Date of Annual General Meeting  
20 March 2009 TR-1: Notification of major interests in shares  
20 March 2009 TR-1: Notification of major interests in shares  
16 March 2009 Final Results for the year ended 31 December 2008  
02 March 2009 TR-1: Notification of major interests in shares  
27 February 2009 Notice of Announcement of 2008 Final Results  
17 February 2009 Chi-Med Announces Completion of Patient Enrolment in its US Phase II Crohn's Disease Clinical Trial of HMPL-004, its Lead Anti-Inflammatory Drug Candidate  
22 January 2009 TR-1: Notification of major interests in shares  
22 January 2009 TR-1: Notification of major interests in shares  
21 January 2009 Holding in Company  
19 January 2009 Director's Shareholding  
08 January 2009 HMPL-002 Clinical Update  
30 December 2008 Blocklisting Six Monthly Return  
23 December 2008 Hutchison MediPharma Limited Enters into Drug Discovery and Development Partnership With Ortho-McNeil-Janssen Pharmaceuticals, Inc.  
15 December 2008 Director's Shareholding  
21 November 2008 Chi-Med Expands Drug Discovery and Development Partnership With Lilly  
30 October 2008 Hutchison MediPharma wins the 2008 American College of Gastroenterology International Award  
08 October 2008 Board Change  
06 August 2008 Interim Results for the Six Months Ended 30 June 2008  
06 August 2008 Drug R&D Division
New employee share option scheme in Hutchison MediPharma
 
18 July 2008 Notice of 2008 Interim Results  
30 June 2008 Blocklisting Six Monthly Return  
10 June 2008 Director's Shareholding  
02 June 2008 Board Change  
23 May 2008 China Healthcare Division Chi-Med increases ownership of its Hutchison Healthcare joint venture  
19 May 2008 Expansion of Consumer Products division Sen launches in 125 Marionnaud beauty stores  
09 May 2008 Results of Annual General Meeting  
22 April 2008 Holding in Company  
09 April 2008 Annual Report 2007 and Notice of Annual General Meeting  
31 March 2008 Holding in Company  
19 March 2008 Preliminary Results for the year ended 31 December 2007  
29 February 2008 Chi-Med Announces Start of Patient Enrolment in a Global Phase IIb Ulcerative Colitis Clinical Trial of HMPL-004, its Leading Anti-Inflammatory Drug Candidate  
28 February 2008 Change in the Registered Office Address in the Cayman Islands  
28 February 2008 Notice of 2007 Preliminary Results  
21 January 2008 Strong growth in China Healthcare division
Streamlining of product range set to further improve financial performance
 
27 December 2007 Block Admission Return  
22 November 2007 Chi-Med Plans to Initiate Global Phase IIb Trials of its Lead Anti-Inflammatory Drug Candidate, HMPL-004, in Ulcerative Colitis Patients  
20 August 2007 Chi-Med Announces Drug Discovery and Development Agreement with Eli Lilly and Company  
09 August 2007 Interim Results for the Six Months Ended 30 June 2007  
18 July 2007 Notice of Interim Results  
02 July 2007 Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis  
22 June 2007 Block Admission  
18 June 2007 Chi-Med locks-in property gain and protects low cost R&D structure through acquisition of Shanghai facility  
23 May 2007 Chi-Med completes patient enrolment on its HMPL-004 ulcerative colitis proof-of-concept; Phase II clinical trial in China  
22 May 2007 Director's Shareholding  
11 May 2007 Results of Annual General Meeting  
12 April 2007 Annual Report and Accounts 2006 - Notice of Annual General Meeting  
02 April 2007 Board Change  
23 March 2007 Director's Shareholding  
21 March 2007 Preliminary Results for the year ended 31 December 2006  
26 February 2007 Notice of Preliminary Results  
17 January 2007 Related party transaction Chi-Med formalises China Sales and Distribution Arrangements  
05 January 2007 Appointment of Joint Broker  
20 November 2006 Chi-Med and Merck KGaA Start Collaboration to Discover Novel Small Molecule Anti-Cancer Drugs  
06 November 2006 Development Agreement with Procter & Gamble for the Discovery and Development of New Active Ingredients for Beauty Products  
29 September 2006 Appointment of Senior Independent Director  
09 August 2006 Financial Results for the Six Months Ended 30 June 2006  
26 July 2006 Notice of Maiden Interim Results  
17 July 2006 Trading Update  
04 July 2006 Chi-Med plans to broaden clinical trials of its leading oncology drug candidate